Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Atypical teratoid/rhabdoid tumoroids reveal subgroup-specific drug vulnerabilities

5 Apr 2023

Abstract excerpt

Atypical teratoid/rhabdoid tumors (ATRTs) represent a rare, but aggressive pediatric brain tumor entity. They are genetically defined by alterations in the SWI/SNF chromatin remodeling complex members SMARCB1 or SMARCA4. ATRTs can be further classified in different molecular subgroups based on their epigenetic profiles. Although recent studies suggest that the different subgroups have distinct clinical features,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Chromatin Remodeling and Cancer
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37020038
DOI: 10.1038/s41388-023-02681-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Atypical teratoid/rhabdoid tumoroids reveal subgroup-specific drug vulnerabilitiesPMID 37020038Read ↗

Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes.Semantic proximity Read ↗

Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors.Semantic proximity Read ↗

Atypical Teratoid Rhabdoid Tumour : From Tumours to TherapiesSemantic proximity Read ↗

AT-21INTEGRATED (EPI)GENOMIC ANALYSES IDENTIFY SUB-GROUP SPECIFIC THERAPEUTIC TARGETS IN CNS RHABDOID TUMORSSemantic proximity Read ↗

Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumorsSemantic proximity Read ↗

Atypical teratoid/rhabdoid tumors—current concepts, advances in biology, and potential future therapiesSemantic proximity Read ↗

Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases.Semantic proximity Read ↗

Development and epigenetic regulation of Atypical teratoid/rhabdoid tumors in the context of cell-of-origin and halted cell differentiationSemantic proximity Read ↗

Current Molecular and Clinical Landscape of ATRT – The Link to Future TherapiesSemantic proximity Read ↗

Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration.Semantic proximity Read ↗

Genome-wide CRISPR and small-molecule screens uncover targetable dependencies in ATRTSemantic proximity Read ↗

Subgroup-Specific Diagnostic, Prognostic, and Predictive Markers Influencing Pediatric Medulloblastoma TreatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.